The European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and Manufacturers of America have expressed interest in lobbying against the campaign.[40] Campaign supporters criticized Hoffmann-La Roche's plans to be more open but not to the extent requested by AllTrials.[41][42]